Search Results

BACK FAPSI English Downloads Download PDF Download DOC

BACK FACT-AntiA English Downloads Download PDF Download DOC

BACK NFCSI-19 English Downloads Download PDF Download DOC

BACK NFLSI-17 English Downloads Download PDF Download DOC

FACIT Utilities Utility Assessment “Utilities” can broadly be defined as methods to measure health outcomes using preferences (either an individual’s or societal). In this way researchers can examine not just a quantity of life-years gained from an intervention, but the quality of that time. Utility is the metric used to quality adjust survival, i.e. to obtain the quality adjusted life year (QALY). Thus, c ost utility analysis (CUA) permits the evaluation of health outcomes adjusted by patient preferences. For example, using CUA, researchers may compare the value of extending a life versus the side effects of the intervention. There are different approaches to capturing preferences, including Time-Trade-Off (TTO), Standard-Gamble (SG), and Discrete Choice Experiments (DCE). However, because preferences/utilities are subjective, they can be influenced by many factors, including culture, disease, and change over time. Because cultures differ across countries, country-specific utilities may be required. Given the unique preferences of varying patient populations and country-specific payment systems for healthcare treatment, there are ongoing discussions of the value of disease- and country-specific utility weights and value sets. ​ Recommendations: The FACT-8D , developed by Dr. Madeleine King and her team, has produced the best direct measure. The FACT-8D is based on the FACT-G, one of the most widely-used cancer-specific HRQL measures and included as part of the core of a large suite of FACT measurements. Utilities can be scored from FACT-G data using the FACT-8D scoring algorithm. This can be done prospectively or retrospectively, facilitating the inclusion of FACT-G data in economic evaluation and health technology assessment. Importantly, the FACT-8D captures dimensions reflecting cancer symptoms and impact that are not included in generic instruments, specifically nausea, fatigue, sleep problems and worry about future health. Finally, the utilities provided by the FACT-8D's algorithm have a stronger theoretical base than those derived from mapping algorithms. Select FACT/FACIT Utilities Citations FACT-8D : King et al 2021 VIH FACT-8D Development and Australian Value Set Herdman et al 2020 JPRO Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L King et al 2016 VIH FACT 8D and EORTC MAUI.pdf (abstract) King ISOQOL2016_poster_FACT-8D-Aust_FINAL.pdf Other FACT Utility Measures : Pickard et al 2012 VIH Comparison of FACT and EQ-5D utilities Dobrez et al 2007 VIH FACT-G Utilities.pdf Kind et al 2005 Pharmacoeconomics FACT-LUI Mapping algorithms to calculate utilities from FACT-G data : ​ Teckle et al 2013 HQLO Mapping the FACT-G to SF-6D and EQ-5D.pdf Askew et al 2011 VIH FACTM to EQ5D .pdf Cheung et al Mapping Eng & Chi FACT-G to EQ5D 2009.pdf Wu et al 2007 VIH on mapping FACTP to EQ-5D.pdf Hess Comparing FACT Utility Estimates_SMDM poster DRAFT1.pdf FACIT Utility Mapping Slides_2004.ppt ​

BACK NVMBQ English Downloads Download PDF - Patient Download DOC - Patient Download PDF - Provider Download DOC - Provider

BACK NFKSI-19 English Downloads Download PDF Download DOC

BACK FKSI-DRS English Downloads Download PDF Download DOC

BACK PROMIS Item Bank v1.0 Dyspnea Severity English Downloads Download PDF Download DOC

FACT-G7 Functional Assessment of Cancer Therapy – General – 7 Item Version Can be used with patients of any tumor type LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – General – 7 Item Version (FACT-G7) is a shortened, 7-item version of the FACT-G designed to quickly and effectively capture the most relevant issues to cancer patients in a valid and reliable manner. Development included oncology patients with advanced cancer from 11 disease sites who ranked the symptoms and concerns they viewed as ‘the very most important’ when undergoing cancer treatment and completed the FACT-G. Of the highest priority cancer-related symptoms and concerns endorsed by patients for inclusion in the FACT-G7, fatigue and ability to enjoy life were ranked the most highly. The FACT-G7 can be used to rapidly assess top-rated symptoms and concerns for a broad spectrum of advanced cancers in clinical practice and research, as well as for quality reporting in cancer chemotherapy and radiation. MEASURE NAME: Functional Assessment of Cancer Therapy – General – 7 Item Version (FACT-G7) VERSION: 4 NUMBER OF ITEMS: 7 PATIENT POPULATION: Cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical well-being, Emotional Well-Being, Functional Well-Being TIME FOR COMPLETION: less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. RELATED MEASURES: FACT-G , FACT-GP , FANLTC DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-G7 can be obtained by registering for permission. Users are not permitted to translate the FACT-G7 without permission from FACIT.org. Permission from FACIT.org to translate the FACT-G7 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. ​ Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References King, M., Agar, M., Currow, D., Hardy, J., Fazekas, B., & McCaffre, N. Assessing quality of life in palliative care settings: head-to-head comparison of four patient-reported outcome measures (EORTC QLQ-C15-PAL, FACT-Pal, FACT-Pal-14, FACT-G7). Supportive Care in Cancer 2020; 28:141–153. doi: 10.1007/s00520-019-04754-9. Yanez B., Pearman T., Lis C.G., Beaumont J.L., Cella D. The FACT-G7: A rapid version of the Functional Assessment of Cancer Therapy – General (FACT-G) for monitoring symptoms and concerns in oncology practice and research. Annals of Oncology 2013; 24: 1073-1078. doi:10.1093/annonc/mds539. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Pearman,T., Yanez B., Peipert, J., Wortman K., Beaumont J., & Cella D. Ambulatory cancer and US general population reference values and cutoff scores for the Functional Assessment of Cancer Therapy. Cancer 2014: 2902-2909. doi: 10.1002/cncr.28758. Webster, K., Cella, D., & Yost, K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-G Functional Assessment of Cancer Therapy - General LEARN MORE FACT-GP Functional Assessment of Cancer Therapy - General Population LEARN MORE FANLTC Functional Assessment of Non-Life Threatening Conditions LEARN MORE

BACK FACIT Item GP5 English Downloads Download PDF Download DOC

PRRS Patient Roles and Responsibilities Scale For cancer patients LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Patient Roles and Responsibilities Scale (PRRS) was developed to enable a broader evaluation of the impact of cancer and cancer treatment, measuring ‘real world’ roles and responsibilities such as caring for others and financial and employment responsibilities. MEASURE NAME: Patient Roles and Responsibilities Scale (PRRS) VERSION: 1 NUMBER OF ITEMS: 18 to 25 PATIENT POPULATION: Cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Responsibilities and Social Life, Family Well-being, Financial Well-Being, Jobs and Careers TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template RELATED MEASURES: CRRS , FACT-G Caregiver , FACT-G7 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the PRRS can be obtained when licensing the measure. Users are not permitted to translate the PRRS without prior permission from FACIT.org. Permission may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor of the PRRS. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Shilling, V., Starkings, R., Jenkins, V. et al. Development and validation of the patient roles and responsibilities scale in cancer patients. Qual Life Res 27 , 2923–2934 (2018). https://doi.org/10.1007/s11136-018-1940-2. LICENSE THIS MEASURE Related Measures Related Measures CRRS Caregiver Roles and Responsibilities Scale LEARN MORE FACT-G Caregiver Functional Assessment of Cancer Therapy – General – Caregiver Version LEARN MORE FACT-G7 Functional Assessment of Cancer Therapy - General - 7 Item Version LEARN MORE